Lyotropic Liquid Crystalline Nanosystems for Bioactive Macromolecule Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of bioactive macromolecules, such as peptides and proteins, face challenges with stability and bioavailability, particularly during oral delivery, where stability in gastric and intestinal environments is a significant concern.
Innovation Solution
The development of physicochemically stable nanostructured colloidal systems in the form of lyotropic liquid crystals, comprising glycerol monooleate, a salt of medium-chain fatty acid or its derivative, an amphiphilic block copolymer, and a bioactive macromolecule with peptide bonds, which provides a nanocompartmentalized structure for enhanced stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GMO is used as an emulsifier to form liquid crystal structures, then the structures are thermodynamically stable and suitable for drug entrapment, but the structures are not physicochemically stable for long time due to hydrolysis and oxidation
Solution Approach 1:
The patent introduces salts of medium-chain fatty acids (C6-C12) as intermediary substances that mediate between the thermodynamic stability requirement and the physicochemical stability need. These salts interact with GMO to form stable complexes that prevent hydrolysis and oxidation while maintaining the liquid crystal structure's thermodynamic stability and drug entrapment capability.
Solution Approach 2:
The patent creates a composite system by combining GMO with salts of medium-chain fatty acids and amphiphilic block copolymers. This composite material approach allows the system to simultaneously achieve thermodynamic stability for drug entrapment and enhanced physicochemical stability against hydrolysis and oxidation, resolving the contradiction between these two stability requirements.
2Reliability
If enteric coating or permeation enhancers or chemical modification are used to address stability and bioavailability, then most problems are addressed, but the complexity of the formulation increases
Solution Approach 1:
The patent employs amphiphilic block copolymers that perform multiple functions simultaneously: they stabilize the liquid crystal structure, enhance the bioavailability of macromolecules, and provide protection against degradation. This multi-functionality approach addresses multiple formulation challenges with a single additive, reducing overall formulation complexity while maintaining reliability.
Solution Approach 2:
The amphiphilic block copolymers act as intermediary substances that facilitate both stability and bioavailability enhancement without requiring separate enteric coating or permeation enhancer components. This intermediary approach consolidates multiple functions into one substance, simplifying the formulation while achieving the desired reliability outcomes.
3Ease of operation
If conventional nanoparticles are used to encapsulate pharmaceutically active substances, then delivery through intestinal tract is enabled, but the stability of the pharmaceutical forms is insufficient
Solution Approach 1:
The patent develops a composite nanoparticle system combining GMO, salts of medium-chain fatty acids, and amphiphilic block copolymers. This composite structure provides both the delivery capability through the intestinal tract and the enhanced stability of pharmaceutical forms, simultaneously addressing both requirements that conventional nanoparticles fail to meet together.
Solution Approach 2:
The salts of medium-chain fatty acids and amphiphilic block copolymers serve as intermediary substances that enhance the stability of the nanoparticle pharmaceutical forms while maintaining the delivery capability through the intestinal tract. These intermediaries bridge the gap between delivery functionality and pharmaceutical stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These lyotropic liquid crystalline nanoparticles exhibit high flexibility in encapsulating various bioactive macromolecules, maintaining physicochemical stability over time, and resisting degradation in simulated gastric and intestinal fluids, thereby enhancing bioavailability.
Implementation Method 1
Amphiphilic molecules present different properties between their distinct structural parts (hydrophilic-hydrophobic, polar-nonpolar), and are self-assembled to supramolecular structures with a morphology which is highly dependent from their chemical nature, their concentration and the solvent medium.
Implementation Method 2
The amphiphilic character of GMO is due to the presence of the hydrophilic glycerol-moiety at the head of the molecule and the hydrophobic hydrocarbon-moiety at the tail of the molecule, thus allowing it to self-assemble in aqueous media forming characteristic, thermodynamically stable liquid crystal structures.
Implementation Method 3
Lyotropic liquid crystals represent an intermediate state of matter between solid and liquid and they are formed through dispersion and self-assembly of amphiphilic molecules to water.
Implementation Method 4
Amphiphilic polymers, like all other amphiphilic molecules, are self-organized to various characteristic structures depending on the dispersion medium.
Data Source
Figure 1a~1c
Figure 2a~2b
AI summary
The invention relates to compositions of physicochemically stable colloid systems in the form of lyotropic liquid crystals, comprising glycerol monooleate, a salt of C6-C12 fatty acid or its derivative with an aromatic substituent, an amphiphilic block copolymer with the chemical formula H(OCH2CH2)a(OCH(CH3)CH2)b(OCH2CH2)aOH, wherein 2≤a≤150 and 15≤b≤70, and a bioactive macromolecule having peptide bonds.